MAP2K7 and neoplasm: Similar results were demonstrated regarding the Vemurafenib + Cobimetinib (BRAF therapy + MEK inhibitor) combined treatment of BRAF-induced craniopharyngioma, which found that of 16 participants, 15 had a medium tumor reduction of 83% [61].